Latest News and Press Releases

Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability...

Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study...

Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of...

Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on...

Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical...

NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral...

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in...